AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative ... and Pfizer’s Velsipity (etrasimod) – both S1P inhibitors – and AbbVie’s JAK inhibitor Rinvoq (upadacitinib).

The new guidance emerged on the same day that Velsipity (etrasimod) was approved by the Medicines ... It’s not the first drug in the class to become available for patients with moderate to ...

Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...

With a U.S. green light for its encapsulated cell therapy technology in the bag, privately held biotech Neurotech ...

Doron Therapeutics, a clinical-stage biotechnology company based in Chapel Hill, has received a Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration ...

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

The FDA granted fast track designation to ATSN-201 for the treatment of X-linked retinoschisis, according to a press release ...

Up to 40% of people who suffer from depression are unable to find any relief for their condition. But now, Blessing ...

President Donald Trump's approval ratings held steady during his first month in office, despite the chaotic start that included mass firings of federal workers, a flurry of executive actions ...

Brittany Craiglow, MD, FAAD, analyzed the promising use of baricitinib for severe pediatric alopecia areata. She highlighted late-breaking data from the BRAVE-AA-PEDS study (NCT05723198 ...

Celltrion said on Monday that its biosimilar Omlyclo had received market authorization for U.S. release. The drug, referencing Xolair, can treat multiple allergic conditions including moderate to ...